← Eichor
Study identifier: NCT06657781 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study and Role of Inflammasome in Platelet Activation During Bacterial And/or Viral Sepsis

Condition: Bacterial Sepsis  ·  Sponsor: Centre Hospitalier Universitaire de la Guadeloupe

PhaseN/A
Planned participants171
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

: Sepsis, now defined as life-threatening organ dysfunction due to a dysregulated host response to infection, is an important global health problem representing about a fifth of all global deaths. It can be associated, in some cases, with multiple organ failure and cytokine storm. The main objective of this study is to estimate and to compare the activation rate of the Nucleotide-binding domain Leucine Rich repeat containing Protein 3 (NLRP3) inflammasome in platelets between five groups of patients suffering from bacterial and/or viral sepsis, with different severity levels according to Sequential Organ Failure Assessment (SOFA) score to precise the platelets' implication in this cytokine storm.

This description comes directly from the study's public registry record.

Talk to the study team

Frédéric MARTINO, Doctor  ·  +590 590 89 10 10  ·  frederic.martino@chu-guadeloupe.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Centre Hospitalier Universitaire de la GuadeloupLes Abymes, Guadeloupe, GuadeloupeRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06657781